Breaking News
Top News
-
Cantor Fitzgerald Downgrades ADMA Biologics Inc. (ADMA) to Neutral From Overweight
-
B. Riley Lifts PT on Theravance Biopharma (TBPH) to $17 From $14
-
Guggenheim Cuts PT on Valneva SE (VALN) to $11 From $13
-
Ocular Therapeutix (OCUL) Announces Additional Positive Data From the SOL-1 Phase 3 Superiority Trial of AXPAXLI
-
Is Vir Biotechnology (VIR) One of the Best Low Priced Biotech Stocks to Invest In?
-
Why Mesoblast Limited (MESO) is One of the Best Low Priced Biotech Stocks to Invest in
-
H.C. Wainwright Initiates Coverage of Generate Biomedicines (GENB) With a Buy Rating
-
Canaccord Initiates Coverage of Biohaven Ltd. (BHVN) With a Buy Rating
-
JonesResearch Initiates Coverage of Relay Therapeutics (RLAY) With a Hold Rating
-
Wells Fargo Cuts PT on Nurix Therapeutics (NRIX) to $28 From $29
-
Mizuho Cuts PT on ADMA Biologics Inc. (ADMA) to $24 From $30
-
Travere Therapeutics (TVTX) Climbs 40.8% on Filspari Approval
-
Airbus to Buy French Cybersecurity Company Quarkslab
-
Inox Clean Is Said to Revive Plan for Up to $1 Billion India IPO
-
India Bond Clearing House Said to Apply for European Recognition
-
UK Job Cuts Suggest Companies Turning Cautious on Iran War
-
Brevan Howard Plans Tokyo Office, to Hire Traders in Hub Boost
-
China Bonds Set for Best Month Since October on Ample Cash
-
Mythos Access Must Be Granted on Level Playing Field, Nagel Says
-
Asia’s Largest Oil Buyers Are Running Low on Hormuz Alternatives
2026-02-05


































